Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DYN
stocks logo

DYN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.781
-11.23%
--
--
-0.852
-18.89%
--
--
-0.880
-9.28%
Estimates Revision
Stock Price
Go Up
up Image
+45.22%
In Past 3 Month
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 34.90 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 34.90 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 20.650
sliders
Low
11.00
Averages
34.90
High
48.00
Current: 20.650
sliders
Low
11.00
Averages
34.90
High
48.00
Bernstein
Market Perform
maintain
$12 -> $21
2025-11-25
Reason
Bernstein
Price Target
$12 -> $21
2025-11-25
maintain
Market Perform
Reason
Bernstein raised the firm's price target on Dyne Therapeutics to $21 from $12 and keeps a Market Perform rating on the shares. The firm sees Dyne's risk-reward as favorable even following the recent move. Next catalyst is for DYN-251 in Duchenne Muscular Dystrophy with data for the registrational expansion cohort.
JPMorgan
Neutral
downgrade
$18 -> $17
2025-11-14
Reason
JPMorgan
Price Target
$18 -> $17
2025-11-14
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Dyne Therapeutics to $17 from $18 and keeps a Neutral rating on the shares. The firm updated the company's model.
Oppenheimer
Andreas Argyrides
Perform
downgrade
$13 -> $11
2025-11-12
Reason
Oppenheimer
Andreas Argyrides
Price Target
$13 -> $11
2025-11-12
downgrade
Perform
Reason
Oppenheimer analyst Andreas Argyrides lowered the firm's price target on Dyne Therapeutics (DYN) to $11 from $13 and keeps a Perform rating on the shares following quarterly results and business update. The firm continues to see upcoming Phase 1/2 DELIVER expansion cohort data for DYNE-251/DMD in December 2025 as an important clearing event, supporting a potential BLA submission for accelerated approval in Q2 2026. In October, Novartis (NVS) announced the acquisition of competitor Avidity. While the deal broadly provided positive readthrough to antisense oligonucleotides for rare diseases, the firm sees the deal reinforcing its thesis that Dyne's programs require further derisking on safety before assigning additional value.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$38 -> $46
2025-11-06
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$38 -> $46
2025-11-06
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Dyne Therapeutics to $46 from $38 and keeps a Buy rating on the shares. The firm believes Dyne's dual Breakthrough programs in myotonic dystrophy and Duchenne muscular dystrophy are now entering registrational stages with "validated functional and biomarker data. This positions the company for clinical catalysts and as a strategic takeover asset, the analyst tells investors in a research note. The Avidity acquisition "sets a clear benchmark, and Dyne's more mature dataset strengthens the case for a higher premium takeout," contends H.C. Wainwright.
Evercore ISI
Gavin Clark-Gartner
Outperform
maintain
$41 -> $38
2025-11-06
Reason
Evercore ISI
Gavin Clark-Gartner
Price Target
$41 -> $38
2025-11-06
maintain
Outperform
Reason
Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics to $38 from $41 and keeps an Outperform rating on the shares. Dyne faces a slight delay in U.S. site activation, pushing back the completion of its registrational cohort enrollment to 2Q26, the analyst tells investors in a research note. Despite this, the firm noted that nearly half of the study is already enrolled, and there's no specific requirement for U.S.-based participants.
Raymond James
Outperform -> Strong Buy
upgrade
$35
2025-08-25
Reason
Raymond James
Price Target
$35
2025-08-25
upgrade
Outperform -> Strong Buy
Reason
Raymond James upgraded Dyne Therapeutics to Strong Buy from Outperform with a $35 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dyne Therapeutics Inc (DYN.O) is -6.08, compared to its 5-year average forward P/E of -5.39. For a more detailed relative valuation and DCF analysis to assess Dyne Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.39
Current PE
-6.08
Overvalued PE
-2.21
Undervalued PE
-8.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.70
Undervalued EV/EBITDA
-6.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

DYN News & Events

Events Timeline

(ET)
2025-11-05
16:53:40
Dyne Therapeutics confirms Z-rostudirsen is on schedule for launch in Q1 2027
select
2025-11-05
16:53:04
Dyne Therapeutics Announces Q3 Earnings Per Share of 76 Cents, Below Consensus Estimate of 85 Cents
select
2025-10-27 (ET)
2025-10-27
12:00:56
Dyne Therapeutics Sees 41.7% Increase
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-03NASDAQ.COM
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

  • Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.

  • Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.

  • Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.

  • General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.

[object Object]
Preview
6.5
11-22NASDAQ.COM
Reasons Behind Dyne Therapeutics Stock Surge This Week

  • Positive Analyst Note: Dyne Therapeutics received a favorable mention in an analyst report from RBC Capital Markets, highlighting its potential in the biotech sector, which has seen a recent rally, leaving some stocks behind.

  • Stock Performance: Following the analyst note, Dyne's stock rose by 11% week-to-date, reflecting investor optimism about the company's prospects in developing therapies for muscle disorders.

  • Market Trends: The RBC report suggests that investors are shifting focus from AI/tech stocks to biotech, indicating a potential for further growth in the sector, particularly for companies like Dyne, Acadia Pharmaceuticals, and others that were overlooked in the recent rally.

  • Investment Considerations: While Dyne Therapeutics shows promise, it was not included in the Motley Fool Stock Advisor's list of the top 10 stocks to buy, which historically have provided significant returns compared to the broader market.

[object Object]
Preview
2.0
11-18Benzinga
Major Stocks on the Rise Monday: Jazz Pharmaceuticals, Sigma Lithium, Zymeworks, and More

  • U.S. Stock Market Overview: U.S. stocks declined on Monday, with the Dow Jones index dropping over 100 points, while several individual stocks saw significant gains.

  • Jazz Pharmaceuticals Surge: Jazz Pharmaceuticals' shares rose 18% to $166.56 following positive results from a Phase 3 trial for its cancer treatment Ziihera.

  • Notable Stock Performances: PACS Group's shares jumped 49.5%, Sigma Lithium gained 30.5%, and Zymeworks rose 29.5%, among other notable stock increases.

  • Analyst Upgrades and Positive Data: Companies like Vita Coco and Alto Neuroscience received analyst upgrades, contributing to their stock price increases, while several firms reported strong clinical trial results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dyne Therapeutics Inc (DYN) stock price today?

The current price of DYN is 20.65 USD — it has increased 2.79 % in the last trading day.

arrow icon

What is Dyne Therapeutics Inc (DYN)'s business?

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.

arrow icon

What is the price predicton of DYN Stock?

Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 34.90 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dyne Therapeutics Inc (DYN)'s revenue for the last quarter?

Dyne Therapeutics Inc revenue for the last quarter amounts to -113.89M USD, increased 7.79 % YoY.

arrow icon

What is Dyne Therapeutics Inc (DYN)'s earnings per share (EPS) for the last quarter?

Dyne Therapeutics Inc. EPS for the last quarter amounts to -109964000.00 USD, increased 46.85 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dyne Therapeutics Inc (DYN)'s fundamentals?

The market is revising No Change the revenue expectations for DYN for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 45.22%.
arrow icon

How many employees does Dyne Therapeutics Inc (DYN). have?

Dyne Therapeutics Inc (DYN) has 191 emplpoyees as of December 05 2025.

arrow icon

What is Dyne Therapeutics Inc (DYN) market cap?

Today DYN has the market capitalization of 2.95B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free